✦ LIBER ✦

Thalidomide plus topotecan for recurrent ovarian cancer?

✍ Scribed by Adrian Burton

Book ID: 117784653
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 76 KB
Volume: 9
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(08)70061-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topotecan plus cyclophosphamide in recur

Topotecan plus cyclophosphamide in recurrent ovarian cancer

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 134 KB

Thalidomide + topotecan improves respons

Thalidomide + topotecan improves response in ovarian cancer

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Prolonged topotecan beneficial for recur

Prolonged topotecan beneficial for recurrent ovarian cancer

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Weekly topotecan for recurrent platinum

Weekly topotecan for recurrent platinum resistant ovarian cancer

✍ Fadi Abushahin; Diljeet K. Singh; John R. Lurain; Edward C. Grendys; Alfred W. R 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Examining the role of topotecan in recur

Examining the role of topotecan in recurrent ovarian cancer

📂 Article 📅 1997 🏛 Adis International Limited (now part of Wolters Kl ⚖ 298 KB

A prospective randomized trial of thalid

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

✍ Levi S. Downs Jr.; Patricia L. Judson; Peter A. Argenta; Rahel Ghebre; Melissa A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. ## METHODS. Women were enrolled i